IMMUNEONCO-B(01541): The National Medical Products Administration has approved the IND application of IMM0306S (subcutaneous formulation) for the treatment of systemic lupus erythematosus.

IMMUNEONCO-B (01541) Announces that the Board of Directors of the Company has noticed recent unusual fluctuations in the company's stock price. After making reasonable inquiries, the Board of Directors confirms that as of the date of this announcement, they are not aware of any information that needs to be disclosed to avoid false market for the company's securities, or any insider information that needs to be disclosed under the Securities and Futures Ordinance (Chapter 571) of Hong Kong. As of the date of this announcement, the Board of Directors confirms that the Group's business operations and clinical development remain normal, and there have been no significant adverse changes in the Group's business operations and financial conditions. Furthermore, the Board of Directors is pleased to announce that the Group has obtained approval from the National Medical Products Administration of the People's Republic of China (NMPA) for the new drug clinical trial (IND) application of IMM0306S (subcutaneous formulation) for the treatment of Systemic Lupus Erythematosus (SLE). IMM0306S (subcutaneous formulation) is a subcutaneous formulation developed based on IMM0306. IMM0306, independently developed by the Group, is a bispecific molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20), and is the world's first CD47 and CD20 bispecific molecule to enter clinical stage. IMM0306 blocks the "don't eat me" signal by inhibiting CD47-SIRP interaction, activates macrophages and NK cells by enhancing Fc-FcRIIa and Fc-FcRIIIa interactions, and effectively eliminates malignant B cells by preferentially binding to CD20 rather than CD47, while minimizing toxicity to improve treatment efficacy. As of the date of this announcement, the Group holds global intellectual property and commercialization rights for IMM0306S (subcutaneous formulation).